Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advantan fatty ointment dose-duration vasoconstriction study in healthy volunteers
ACTRN12619000510145Phase 4Completed
- Sponsor
- Zenith Technologies
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylprednisolone aceponate in atopic dermatitis (AD) and psoriasis, sponsored by Zenith Technologies. Primary endpoints: ED50 parameter, D1 parameter and 1 more. Started Apr 2019; status: completed.
02
Drugs
methylprednisolone aceponate
03
Conditions
atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on ACTRN12619000510145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000510145.